SCHEMBL2675429

SCHEMBL2675429

NC(=O)CN1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 5/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 4/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
P4HB P07237 1/20 0.38
MCL1 Q07820 1/20 0.36
GAA P10253 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676766 0.87 MCL1 (0.46) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2676392 0.87 MAPK1 (0.45) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2675569 0.87 ALDH1A1 (0.46) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2677324 0.86 MAPT (0.51) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2675780 0.86 ALDH1A1 (0.48) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2677517 0.85 ALDH1A1 (0.47) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2676750 0.85 ALDH1A1 (0.47) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL2675627 0.85 RAB9A (0.40) NPSR1L3MBTL1ALDH1A1LMNAKDM4E
SCHEMBL2675924 0.85 DRD4 (0.42) NPSR1L3MBTL1MAPK1ALDH1A1LMNA
SCHEMBL1718457 0.85 ALDH1A1 (0.52) NPSR1ALDH1A1KDM4EPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 SLC2A1 3283/4885NPSR1 182/4885L3MBTL1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.